Tp53 in dlbcl

Author: xoej

August undefined, 2024

Splet28. apr. 2024 · Sequencing data showed that the RC-K8 cell line harbours a largely normal TP53 gene with a benign P72R polymorphism but with a relatively high expression level of its negative regulator MDM2... Splet14. okt. 2016 · TP53 is a well-known tumor suppressor gene that is involved in many cell functions including cell cycle arrest, DNA repair, and activation of the pro-apoptotic …

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell

Splet09. nov. 2024 · TP53 mutations in DLBCL have been identified as markers of poor prognosis and are often associated with therapeutic resistance. Chimeric antigen … Splet13. dec. 2016 · Schematic overview of the mutational pattern of CD58 and TP53 genes in DLBCL. Distinct gene mutations in 165 cases of DLBCL, NOS were described. A. … hyundai tucson townsville

Comprehensive Analysis of TP53 Mutation Characteristics and ...

Splet10. nov. 2024 · TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown. Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two … Splet10. apr. 2024 · TP53 mutations are critically involved in tumor progression and indicate poor prognosis in DLBCL. 20, 21, 22 Despite diversity in gene mutations correlated with TP53 mutations among the... Splet13. dec. 2016 · Interestingly, TP53 mutations were found to be significantly more common in DLBCL with MYC translocations ( r = 0.446, P = 0.034). While no gene mutation was found to be more prevalent in patients with DLBCL with bone marrow involvement, MYD88 mutations were more common in primary DLBCL of the CNS or testis. hyundai tucson transmission recall

Cancers Free Full-Text Influence of TP53 Mutation on Survival …

XPO1 expression worsens the prognosis of unfavorable DLBCL …

Splet04. okt. 2024 · The TP53 gene is mutated in about 20% of cases of DLBCL 9, and most of the published mutations affect p53-DNA interactions, resulting in a partial or complete … Splet13. mar. 2024 · The aim of the current study was to comprehensively explore TP53 gene variability resulting from somatic mutations, promoter methylation, and allelic … hyundai tucson trend leasingSpletThe TP53 gene is involved in maintaining genomic stability in response to DNA damage by activating DNA repair programs and by triggering cell cycle arrest. The loss of TP53 is associated with lymphomagenesis and resistance to chemotherapy. 6 TP53 mutations are present in 10% of DLBCL patients and confer a poor prognosis in patients treated with ... hyundai tucson towbar fitting

"Splet01. jan. 2016 · TP53 is frequently WT in DLBCL associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a, a small molecule that activates the TP53 pathway by … " - Tp53 in dlbcl

Tp53 in dlbcl

XPO1 expression worsens the prognosis of unfavorable DLBCL …

Splet09. nov. 2024 · In DLBCL, TP53 mutations are associated with dismal prognosis due to therapy refractoriness [7,9,10,14–17]. Several molecular mechanisms of drug resistance on the basis of TP53 mutations have been described and were summarized by Hientz et al. [13]. The treatment of DLBCL is challenging. High-dose platin-containing agents in combi- Splet29. mar. 2024 · TP53 mutations also stratified patients with germinal center B cell-like DLBCL, but not nongerminal center B cell-like DLBCL, into molecularly distinct subsets with different survivals. This study shows the prognostic importance of mutations in the TP53 DNA-binding domains in patients with DLBCL.

Did you know?

Splet04. nov. 2024 · In DLBCL/HGBCL cells, Mut-TP53/p53-positive expression predicts resistance to selinexor. INCB057643 synergizes with selinexor in HGBCL-DH cells, overcoming resistance in Mut-TP53/p53-positive HGBCL-DH. These findings warrant future investigation on the role of XPO1, selinexor, and combined BET inhibition in R/R DLBCL …

Splet27. mar. 2024 · This study indicated rrDLBCL patients with TP53 mutations was still the group of poor prognosis in the CAR-T therapy era. CAR-T therapy can benefit some … Splet14. avg. 2024 · Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes...

SpletAccording to the genetic landscape of DLBCL in western countries, the most frequently mutated genes are sequentially KMT2D, MYD88, CREBBP, TP53 and PIM1 (17, 18). In contract, the most frequently mutated genes in Chinese DLBCL patients are sequentially PIM1, BTG2, TP53, HIST1H1E and KMT2D . The higher proportion of non-GCB DLBCL … Splet14. jun. 2024 · TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma. TP53 mutations should be considered for risk models …

Splet10. apr. 2024 · This panel did not include some of the genes used in the most recent DLBCL classifications (such as those described in ref. 46, 47). Nevertheless, it allowed the detection of TP53 mutations, one of the major prognostic genetic factors identified. Our results suggested once again the value of this gene in routine prognostic evaluations.

Splet10. apr. 2024 · As reported in our recent phase 1/2 study, decitabine improved clinical efficacy of R-CHOP on TP53 Mut DLBCL through targeting tumor immune microenvironment. 23,24 Given the above evidence that ... molly nilsson zenith kugouSplet01. jan. 2016 · In this review, we summarized recent advances on different mechanisms of TP53 in DLBCL and new therapeutic approaches to overcome TP53 inactivation. Introduction The TP53 gene, initially recognized as an oncogene in 1970s, has been identified as a tumor suppressor gene since 1989 (Lane, 1992), and is recognized as the … hyundai tucson touch screenSplet09. nov. 2024 · Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) is associated with poor outcome. The clinical behavior and genetic landscape of DLBCL is heterogeneous and still not fully understood. TP53 mutations in DLBCL have been identified as markers of poor prognosis and are often associated with therapeutic resistance. Chimeric antigen … hyundai tucson trend hybrid